Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company” or "Solid”), a life sciences company developing precision genetic ...
Ltd. to Further Strengthen DSA Supply Chain; Transaction Expected to be Accretive to Non-GAAP Earnings Per Share by Approximately $0.25 in 2026 and Approximately $0.60 in 2027 –– Exercises Option to ...
ATEC Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Major Strategic AlignmentTheradaptive Initiates Series B to Advance Proprietary ...
About the FALCON Trial FALCON is a first-in-human, open-label, multi-center Phase 1b clinical trial designed to evaluate the safety and tolerability of SGT-212 in participants aged 18-40 who have been ...
XOMA Royalty Corporation ('XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be ...
ATEC Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Major Strategic Alignment Theradaptive Initiates Series B to Advance Proprietary Protein-Engineering Technology ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular ...
There was no money for me to continue raising on a sub small scale plant-based meat company in 2025. That path is over." ...
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter ...
Detailed price information for Bone Biologics Corp WT (BBLGW-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback